First inhaled gene therapy tested for rare lung disorder
NCT ID NCT06600425
Summary
This early-stage study tested the safety of an experimental inhaled medicine called RCT1100 in seven adults with a rare genetic lung disease called Primary Ciliary Dyskinesia (PCD). The goal was to see if the treatment was safe and to gather initial data on whether it could help fix the faulty cilia (tiny hair-like structures) in the lungs. This research is a first step to see if the approach is promising for future, larger studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CILIARY DYSKINESIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Royal Brompton Hospital
London, SW3 6NP, United Kingdom
-
University Hospital Southampton NHS Foundation Trust
Southampton, SO16 6YD, United Kingdom
Conditions
Explore the condition pages connected to this study.